MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION

DOI10.1081/BIP-100101181zbMath0955.62115OpenAlexW2074887877WikidataQ52211232 ScholiaQ52211232MaRDI QIDQ4512728

David Melnychuk, Elizabeth Eisenhauer, Janet Dancey, Benny Zee

Publication date: 27 February 2001

Published in: Journal of Biopharmaceutical Statistics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1081/bip-100101181

zbMATH Keywords

clinical trialmissing dataoncologymultiple-stage stopping rulemultivariate endpoint

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical analysis (62L10)

Related Items

Boundary Crossing Random Walks, Clinical Trials, and Multinomial Sequential Estimation, Design efficiency in dose finding studies, Testing Statistical Hypotheses on Stochastic Ordering of Discrete Distributions

Cites Work

• A Bayesian Approach to the Design of Phase II Clinical Trials
• Designs for Group Sequential Phase II Clinical Trials
• One-Sample Multiple Testing Procedure for Phase II Clinical Trials
• Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• Bivariate Sequential Designs for Phase II Trials